Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at industrialstockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. IndustrialStockMovers.com is also looking into these tickers IEA, LICY, SOL, HDSN, RCMT and more..
Recent RVNC Stock Price: $13.15
Summary: Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
Chris Shibutani analyst at Goldman Sachs reiterates coverage on Revance Therapeutics (RVNC) stock in the energy sector with a Buy rating and has set RVNC's stock price target at $33.
TipRanks.com reports that Revance Therapeutics currently has 5 analysts offering 12-month price targets on RVNC and the consensus is a Strong Buy rating with an average stock price target of $38.60. The most recent RVNC stock price we have is $13.15 and we are not making any RVNC forecasts at this time.
In addition, TradingView issued a Strong sell rating for RVNC over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RVNC. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RVNC, please click here >>
Taysha Gene Therapies, TSHA
Recent TSHA Stock Price: $3.06
Summary: Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Whitney Ijem analyst at Canaccord Genuity reiterates coverage on Taysha Gene Therapies (TSHA) stock in the energy sector with a Buy rating and has set TSHA's stock price target at $6.
TipRanks.com reports that Taysha Gene Therapies currently has 5 analysts offering 12-month price targets on TSHA and the consensus is a Strong Buy rating with an average stock price target of $5.20. The most recent TSHA stock price we have is $3.06 and we are not making any TSHA forecasts at this time.
In addition, TradingView issued a buy rating for TSHA over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TSHA. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on TSHA, please click here >>
Marinus, MRNS
Recent MRNS Stock Price: $7.20
Summary: Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.
Douglas Tsao analyst at H.C. Wainwright reiterates coverage on Marinus (MRNS) stock in the energy sector with a Buy rating and has set MRNS's stock price target at $27.
TipRanks.com reports that Marinus currently has 5 analysts offering 12-month price targets on MRNS and the consensus is a Strong Buy rating with an average stock price target of $22.00. The most recent MRNS stock price we have is $7.20 and we are not making any MRNS forecasts at this time.
In addition, TradingView issued a buy rating for MRNS over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRNS. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MRNS, please click here >>
Boston Scientific, BSX
Recent BSX Stock Price: $54.10
Summary: Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
Robbie Marcus analyst at J.P. Morgan reiterates coverage on Boston Scientific (BSX) stock in the energy sector with a Buy rating and has not provided BSX's stock price target.
TipRanks.com reports that Boston Scientific currently has 4 analysts offering 12-month price targets on BSX and the consensus is a Strong Buy rating with an average stock price target of $61.00. The most recent BSX stock price we have is $54.10 and we are not making any BSX forecasts at this time.
In addition, TradingView issued a Strong buy rating for BSX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BSX. industrialstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BSX, please click here >>
The editors at industrialstockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
IndustrialStockMovers.com keeps investors informed of the top moving stocks within the industrial sector. We provide investors with timely information regarding top moving stocks in the industrial sector sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to IndustrialStockMovers.com.
==============================================================================
